

MYRIAD GENETICS INC
Form 8-K
August 16, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 08/16/2007

Myriad Genetics, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 0-26642

Delaware
(State or other jurisdiction of
incorporation)

87-0494517
(IRS Employer
Identification No.)

320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices, including zip code)

801-584-3600
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Edgar Filing: MYRIAD GENETICS INC - Form 8-K

Information to be included in the report

Item 8.01. Other Events

On August 16, 2007, Myriad Genetics, Inc. announced that it has initiated a third Phase 2 human clinical trial of its therapeutic candidate, Azixa(TM) (MPC-6827), in patients with non-small-cell lung cancer that has spread to the brain. The information in the press release dated August 16, 2007 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits

(d)

Exhibit

Number	Description
--------	-------------

99.1	The Registrant's press release dated August 16, 2007 concerning the initiation of a third Phase 2 human clinical trial of Azixa in patients with non-small-cell lung cancer that has spread to the brain.
------	---

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Myriad Genetics, Inc.

Date: August 16, 2007

By: /s/ Peter D. Meldrum

Peter D. Meldrum
President and Chief Executive Officer

Exhibit Index

Exhibit No.	Description
EX-99.1	The Registrant's press release dated August 16, 2007 concerning the initiation of a third Phase 2 human clinical trial of Azixa in patients with non-small-cell lung cancer that has spread to the brain.